DocWire News spoke with Raj Chakraborty, MD, assistant professor of medicine at Columbia University Irving Medical Center, Division of Hematology/Oncology, on bispecific T-cell engagers (BiTEs) for multiple myeloma, and considerations for selecting between BiTEs and CAR T therapy in the clinic.

This is the third in a four part conversation with Dr. Chakraborty. Watch part one, on recent clinical trials for newly-diagnosed multiple myeloma, and part two, on the challenges of the paradigm shift to quadruplet therapy for this disease.